Key Points
- Director John Smither sold 1,600 shares of NewAmsterdam Pharma for $40,512, reducing his position by 15.44% to 8,760 shares.
- NAMS shares opened at $22.79, near their 12-month low of $22.34 and down 11.1%; the company also reported a quarterly loss of $0.52 per share, missing estimates.
- Analyst sentiment remains broadly positive, with an average “Moderate Buy” rating and a $49.73 price target, though targets range from $45 to $58 and one analyst rates the stock a sell.
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) Director John Smither sold 1,600 shares of the company's stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $25.32, for a total value of $40,512.00. Following the sale, the director directly owned 8,760 shares of the company's stock, valued at $221,803.20. The trade was a 15.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
NewAmsterdam Pharma Stock Down 11.1%
Shares of NAMS stock opened at $22.79 on Thursday. NewAmsterdam Pharma Company N.V. has a 12 month low of $22.34 and a 12 month high of $42.21. The company has a market cap of $2.72 billion, a PE ratio of -10.55 and a beta of 0.09. The business's 50 day moving average is $29.10 and its two-hundred day moving average is $31.37.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.04). The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $2.83 million. NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%. As a group, equities analysts expect that NewAmsterdam Pharma Company N.V. will post -1.82 EPS for the current fiscal year.
NewAmsterdam Pharma News Roundup
Here are the key news stories impacting NewAmsterdam Pharma this week:
- Positive Sentiment: HC Wainwright reaffirmed its Buy rating on NewAmsterdam Pharma and maintained a $52 price target, implying substantial upside from recent trading levels. The bullish view supports the long-term investment case, although it has not prevented near-term selling pressure. Benzinga analyst rating report
- Neutral Sentiment: Recent analyst coverage discussed NewAmsterdam Pharma alongside other healthcare companies, including Dyne Therapeutics, Ionis Pharmaceuticals and Amgen. The reports may influence sector positioning, but the available headlines do not identify a new company-specific development for NAMS. Analyst insights on healthcare companies Analyst insights on Amgen and NewAmsterdam Pharma
- Negative Sentiment: Director John W. Smither sold 1,600 NAMS shares for approximately $40,512, reducing his position by 15.44%. While insider sales can be made for personal or financial reasons, the transaction may add to investor caution when the stock is already under pressure. SEC insider transaction filing
- Negative Sentiment: A sharp trial-related selloff in Novartis and resulting weakness in other biotechnology stocks has likely hurt sentiment toward the broader drug-development sector. The read-through is indirect for NAMS, but it may encourage investors to reduce risk across biotech holdings. Novartis trial-failure market impact
Analysts Set New Price Targets
A number of equities analysts have recently commented on the company. BMO Capital Markets initiated coverage on NewAmsterdam Pharma in a research note on Monday, July 20th. They issued an "outperform" rating and a $58.00 price objective on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. HC Wainwright reiterated a "buy" rating and issued a $52.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday. Jefferies Financial Group restated a "buy" rating and issued a $45.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. Finally, Royal Bank Of Canada reduced their target price on NewAmsterdam Pharma from $51.00 to $50.00 and set an "outperform" rating for the company in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $49.73.
Read Our Latest Report on NewAmsterdam Pharma
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN lifted its stake in NewAmsterdam Pharma by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company's stock worth $32,000 after purchasing an additional 300 shares during the period. KBC Group NV bought a new stake in shares of NewAmsterdam Pharma in the 1st quarter valued at approximately $37,000. Navalign LLC bought a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at approximately $46,000. AdvisorNet Financial Inc acquired a new position in shares of NewAmsterdam Pharma in the 1st quarter worth approximately $82,000. Finally, Empowered Funds LLC bought a new position in shares of NewAmsterdam Pharma during the 4th quarter worth approximately $85,000. Institutional investors and hedge funds own 89.89% of the company's stock.
About NewAmsterdam Pharma
(
Get Free Report)
NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.
The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
